DeepMed Research

SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED

🇮🇳India

Country: 🇮🇳India

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of SPARC1103 in Subjects With Spasticity

Phase 2

Completed

Conditions: Spasticity

Interventions: Drug: SPARC1103 low dose
Drug: SPARC1103 high dose
Drug: SPARC Placebo

First Posted Date: 2014-01-03

Last Posted Date: 2019-05-03

Lead Sponsor: Sun Pharma Advanced Research Company Limited

Target Recruit Count: 142

Registration Number: NCT02027025

Locations: 🇺🇦
SPARC Site 21, Ivano-Frankivs'k, Ukraine
🇺🇦
SPARC Site 23, L'viv, Ukraine
🇺🇸
SPARC Site 4, Long Beach, California, United States

and more 20 locations

Efficacy and Safety of SPARC1310 in Seasonal Allergic Rhinitis

Phase 2

Completed

Conditions: Seasonal Allergic Rhinitis

Interventions: Drug: SPARC1310 II
Drug: SPARC1310 III
Drug: SPARC Placebo
Drug: SPARC1310 I

First Posted Date: 2013-09-12

Last Posted Date: 2019-05-03

Lead Sponsor: Sun Pharma Advanced Research Company Limited

Target Recruit Count: 222

Registration Number: NCT01940146

Locations: 🇨🇦
SPARC Site 1, Kingston, Canada

Safety Study of SPARC1104

Phase 3

Completed

Conditions: Spasticity

Interventions: Drug: SPARC1104 modified dose regimen I
Drug: SPARC1104 modified dose regimen II
Drug: SPARC1104 modified dose regimen III

First Posted Date: 2013-02-22

Last Posted Date: 2019-05-03

Lead Sponsor: Sun Pharma Advanced Research Company Limited

Target Recruit Count: 375

Registration Number: NCT01797185

Locations: 🇺🇸
SPARC Site 11, Port Charlotte, Florida, United States
🇺🇸
SPARC Site 24, Overland Park, Kansas, United States
🇺🇸
SPARC Site 34, Phoenix, Arizona, United States

and more 47 locations

Safety and Efficacy of SPARC1203 in Allergic Rhinitis

Phase 2

Completed

Conditions: Allergic Rhinitis

Interventions: Drug: SPARC1203
Drug: Placebo

First Posted Date: 2012-06-08

Last Posted Date: 2019-05-03

Lead Sponsor: Sun Pharma Advanced Research Company Limited

Target Recruit Count: 159

Registration Number: NCT01614691

Locations: 🇩🇪
SPARC Site 1, Hannover, Germany

Efficacy and Safety of SPARC0921 in Subjects With Spasticity

Phase 3

Completed

Conditions: Spasticity

Interventions: Drug: Placebo0921
Drug: SPARC0921

First Posted Date: 2011-10-21

Last Posted Date: 2019-06-18

Lead Sponsor: Sun Pharma Advanced Research Company Limited

Target Recruit Count: 392

Registration Number: NCT01457352

Locations: 🇺🇸
SPARC Site 56, Columbus, Ohio, United States
🇺🇸
SPARC Site 17, Port Charlotte, Florida, United States
🇺🇸
SPARC Site 36, Costa Mesa, California, United States

and more 70 locations

Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis

Phase 2

Completed

Conditions: Allergic Conjunctivitis

Interventions: Drug: SPARC1102 I
Drug: SPARC1102 II
Drug: SPARC1102 III
Drug: Vehicle

First Posted Date: 2011-03-22

Last Posted Date: 2016-06-24

Lead Sponsor: Sun Pharma Advanced Research Company Limited

Target Recruit Count: 122

Registration Number: NCT01320553

Locations: 🇺🇸
ORA Inc, Andover, Massachusetts, United States

Pharmacokinetic, Safety and Tolerability Study of SPARC1028

Phase 1

Completed

Conditions: Solid Tumor in Advanced Stage

Interventions: Drug: SPARC1028

First Posted Date: 2011-02-28

Last Posted Date: 2019-05-03

Lead Sponsor: Sun Pharma Advanced Research Company Limited

Target Recruit Count: 36

Registration Number: NCT01305512

Locations: 🇺🇸
SPARC Site 1, Buffalo, New York, United States

Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination

Phase 1

Completed

Conditions: Solid Tumor in Advanced Stage

Interventions: Drug: SPARC1023 I
Drug: SPARC1023 II

First Posted Date: 2011-02-25

Last Posted Date: 2019-05-03

Lead Sponsor: Sun Pharma Advanced Research Company Limited

Target Recruit Count: 57

Registration Number: NCT01304303

Locations: 🇺🇸
SPARC Site 1, Buffalo, New York, United States

Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Open Angle Glaucoma
Ocular Hypertension

Interventions: Drug: SPARC0912
Drug: Reference0912

First Posted Date: 2009-07-28

Last Posted Date: 2021-03-09

Lead Sponsor: Sun Pharma Advanced Research Company Limited

Target Recruit Count: 578

Registration Number: NCT00947661

Locations: 🇺🇸
SPARC study site, High Point, North Carolina, United States

Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Ocular Hypertension
Open Angle Glaucoma

Interventions: Drug: SPARC0913

First Posted Date: 2009-07-24

Last Posted Date: 2021-03-09

Lead Sponsor: Sun Pharma Advanced Research Company Limited

Target Recruit Count: 161

Registration Number: NCT00945958

Locations: 🇺🇸
SPARC study site, High Point, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy